drugset / Trial / NCT01120626

Randomized Controlled Study of Donepezil in Fragile X Syndrome

NCT01120626

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Fragile X syndrome (FraX) is the most common known heritable cause of human intellectual disability. Though recent research has revealed much about the genetic and neurobiological bases of FraX, knowledge about specific and effective treatments for affected individuals is lacking. Based on information from both human and animal studies, one cause of intellectual disability in FraX may be related to deficits in a particular brain neurotransmitter system (the "cholinergic" system). Thus, the investigators propose to use a specific medication, donepezil, to augment cholinergic system in adolescents affected by FraX. If found to be effective, the knowledge generated by this research may also be relevant to other developmental disorders that share common disease pathways with FraX.

Timeline

Start
2009-09
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Donepezil Small molecule 2.5 mg
Comparator Donepezil Small molecule 10 mg

Indications